ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000732

Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease

Identifieur interne : 000732 ( PascalFrancis/Corpus ); précédent : 000731; suivant : 000733

Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease

Auteurs : Panida Piboolnurak ; Anthony E. Lang ; Andres M. Lozano ; Janis M. Miyasaki ; Jean A. Saint-Cyr ; Yu-Yan W. Poon ; William D. Hutchison ; Jonathan O. Dostrovsky ; Elena Moro

Source :

Movement disorders [ 0885-3185 ] ; 2007.

RBID : Pascal:07-0314955

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Lévodopa, Long terme, Noyau sousthalamique, Stimulation cérébrale profonde.

English descriptors

KwdEn :
- Deep brain stimulation, Levodopa, Long term, Nervous system diseases, Parkinson disease, Subthalamic nucleus.

Abstract

Subthalamic nucleus deep brain stimulation (STN-DBS) is effective in advanced Parkinson's disease (PD), but its effects on the levodopa response are unclear. We studied the levodopa response after long-term STN-DBS, STN-DBS efficacy and predictive value of preoperative levodopa response to long-term DBS benefit in 33 PD patients with bilateral STN-DBS. Patients were assessed using the Unified Parkinson's Disease Rating Scale preoperatively (with and without medications) and postoperatively (without medications or stimulation, with only medications or stimulation, and with both medications and stimulation). Levodopa response significantly decreased postoperatively by 31.1% at 3 years and 32.3% at 5 years, possibly related to the reduction in medication requirement, direct STN stimulation effect or PD progression. STN-DBS alone significantly improved motor scores (37.2% at 3 years and 35.1% at 5 years) and activities of daily living scores (27.1% at 3 years and 19.2% at 5 years). Anti-PD drugs were significantly reduced by 47.9% at 3 years and 39.8% at 5 years. However, the magnitude of the preoperative response to levodopa did not predict DBS benefit at 3 and 5 years.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 22`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease`
A11	`01`	`1`		`@1 PIBOOLNURAK (Panida)`
A11	`02`	`1`		`@1 LANG (Anthony E.)`
A11	`03`	`1`		`@1 LOZANO (Andres M.)`
A11	`04`	`1`		`@1 MIYASAKI (Janis M.)`
A11	`05`	`1`		`@1 SAINT-CYR (Jean A.)`
A11	`06`	`1`		`@1 POON (Yu-Yan W.)`
A11	`07`	`1`		`@1 HUTCHISON (William D.)`
A11	`08`	`1`		`@1 DOSTROVSKY (Jonathan O.)`
A11	`09`	`1`		`@1 MORO (Elena)`
A14	`01`			`@1 Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital @2 Toronto, Ontario @3 CAN @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 6 aut. @Z 9 aut.`
A14	`02`			`@1 Bumrungrad International Hospital @2 Wattana, Bangkok @3 THA @Z 1 aut.`
A14	`03`			`@1 Department of Neurosurgery, University of Toronto, Toronto Western Hospital @2 Toronto, Ontario @3 CAN @Z 3 aut. @Z 5 aut. @Z 7 aut.`
A14	`04`			`@1 Department of Physiology, University of Toronto @2 Toronto, Ontario @3 CAN @Z 8 aut.`
A20				`@1 990-997`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000149881420130`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 32 ref.`
A47	`01`	`1`		`@0 07-0314955`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Subthalamic nucleus deep brain stimulation (STN-DBS) is effective in advanced Parkinson's disease (PD), but its effects on the levodopa response are unclear. We studied the levodopa response after long-term STN-DBS, STN-DBS efficacy and predictive value of preoperative levodopa response to long-term DBS benefit in 33 PD patients with bilateral STN-DBS. Patients were assessed using the Unified Parkinson's Disease Rating Scale preoperatively (with and without medications) and postoperatively (without medications or stimulation, with only medications or stimulation, and with both medications and stimulation). Levodopa response significantly decreased postoperatively by 31.1% at 3 years and 32.3% at 5 years, possibly related to the reduction in medication requirement, direct STN stimulation effect or PD progression. STN-DBS alone significantly improved motor scores (37.2% at 3 years and 35.1% at 5 years) and activities of daily living scores (27.1% at 3 years and 19.2% at 5 years). Anti-PD drugs were significantly reduced by 47.9% at 3 years and 39.8% at 5 years. However, the magnitude of the preoperative response to levodopa did not predict DBS benefit at 3 and 5 years.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B02U01`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 09`
C03	`03`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 09`
C03	`03`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 09`
C03	`04`	`X`	`FRE`	`@0 Long terme @5 10`
C03	`04`	`X`	`ENG`	`@0 Long term @5 10`
C03	`04`	`X`	`SPA`	`@0 Largo plazo @5 10`
C03	`05`	`X`	`FRE`	`@0 Noyau sousthalamique @5 11`
C03	`05`	`X`	`ENG`	`@0 Subthalamic nucleus @5 11`
C03	`05`	`X`	`SPA`	`@0 Núcleo subtalámico @5 11`
C03	`06`	`X`	`FRE`	`@0 Stimulation cérébrale profonde @4 CD @5 96`
C03	`06`	`X`	`ENG`	`@0 Deep brain stimulation @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso central @5 41`
N21				`@1 204`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 07-0314955 INIST
ET :	Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease
AU :	PIBOOLNURAK (Panida); LANG (Anthony E.); LOZANO (Andres M.); MIYASAKI (Janis M.); SAINT-CYR (Jean A.); POON (Yu-Yan W.); HUTCHISON (William D.); DOSTROVSKY (Jonathan O.); MORO (Elena)
AF :	Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital/Toronto, Ontario/Canada (1 aut., 2 aut., 4 aut., 6 aut., 9 aut.); Bumrungrad International Hospital/Wattana, Bangkok/Thaïlande (1 aut.); Department of Neurosurgery, University of Toronto, Toronto Western Hospital/Toronto, Ontario/Canada (3 aut., 5 aut., 7 aut.); Department of Physiology, University of Toronto/Toronto, Ontario/Canada (8 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2007; Vol. 22; No. 7; Pp. 990-997; Bibl. 32 ref.
LA :	Anglais
EA :	Subthalamic nucleus deep brain stimulation (STN-DBS) is effective in advanced Parkinson's disease (PD), but its effects on the levodopa response are unclear. We studied the levodopa response after long-term STN-DBS, STN-DBS efficacy and predictive value of preoperative levodopa response to long-term DBS benefit in 33 PD patients with bilateral STN-DBS. Patients were assessed using the Unified Parkinson's Disease Rating Scale preoperatively (with and without medications) and postoperatively (without medications or stimulation, with only medications or stimulation, and with both medications and stimulation). Levodopa response significantly decreased postoperatively by 31.1% at 3 years and 32.3% at 5 years, possibly related to the reduction in medication requirement, direct STN stimulation effect or PD progression. STN-DBS alone significantly improved motor scores (37.2% at 3 years and 35.1% at 5 years) and activities of daily living scores (27.1% at 3 years and 19.2% at 5 years). Anti-PD drugs were significantly reduced by 47.9% at 3 years and 39.8% at 5 years. However, the magnitude of the preoperative response to levodopa did not predict DBS benefit at 3 and 5 years.
CC :	002B17; 002B17G; 002B02U01
FD :	Système nerveux pathologie; Parkinson maladie; Lévodopa; Long terme; Noyau sousthalamique; Stimulation cérébrale profonde
FG :	Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux central
ED :	Nervous system diseases; Parkinson disease; Levodopa; Long term; Subthalamic nucleus; Deep brain stimulation
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Central nervous system
SD :	Sistema nervioso patología; Parkinson enfermedad; Levodopa; Largo plazo; Núcleo subtalámico
LO :	INIST-20953.354000149881420130
ID :	07-0314955

Links to Exploration step

Pascal:07-0314955

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease</title>
<author><name sortKey="Piboolnurak, Panida" sort="Piboolnurak, Panida" uniqKey="Piboolnurak P" first="Panida" last="Piboolnurak">Panida Piboolnurak</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Bumrungrad International Hospital</s1>
<s2>Wattana, Bangkok</s2>
<s3>THA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lozano, Andres M" sort="Lozano, Andres M" uniqKey="Lozano A" first="Andres M." last="Lozano">Andres M. Lozano</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurosurgery, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Miyasaki, Janis M" sort="Miyasaki, Janis M" uniqKey="Miyasaki J" first="Janis M." last="Miyasaki">Janis M. Miyasaki</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saint Cyr, Jean A" sort="Saint Cyr, Jean A" uniqKey="Saint Cyr J" first="Jean A." last="Saint-Cyr">Jean A. Saint-Cyr</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurosurgery, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poon, Yu Yan W" sort="Poon, Yu Yan W" uniqKey="Poon Y" first="Yu-Yan W." last="Poon">Yu-Yan W. Poon</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hutchison, William D" sort="Hutchison, William D" uniqKey="Hutchison W" first="William D." last="Hutchison">William D. Hutchison</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurosurgery, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dostrovsky, Jonathan O" sort="Dostrovsky, Jonathan O" uniqKey="Dostrovsky J" first="Jonathan O." last="Dostrovsky">Jonathan O. Dostrovsky</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Physiology, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Moro, Elena" sort="Moro, Elena" uniqKey="Moro E" first="Elena" last="Moro">Elena Moro</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0314955</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0314955 INIST</idno>
<idno type="RBID">Pascal:07-0314955</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000732</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease</title>
<author><name sortKey="Piboolnurak, Panida" sort="Piboolnurak, Panida" uniqKey="Piboolnurak P" first="Panida" last="Piboolnurak">Panida Piboolnurak</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Bumrungrad International Hospital</s1>
<s2>Wattana, Bangkok</s2>
<s3>THA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lozano, Andres M" sort="Lozano, Andres M" uniqKey="Lozano A" first="Andres M." last="Lozano">Andres M. Lozano</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurosurgery, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Miyasaki, Janis M" sort="Miyasaki, Janis M" uniqKey="Miyasaki J" first="Janis M." last="Miyasaki">Janis M. Miyasaki</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saint Cyr, Jean A" sort="Saint Cyr, Jean A" uniqKey="Saint Cyr J" first="Jean A." last="Saint-Cyr">Jean A. Saint-Cyr</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurosurgery, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poon, Yu Yan W" sort="Poon, Yu Yan W" uniqKey="Poon Y" first="Yu-Yan W." last="Poon">Yu-Yan W. Poon</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hutchison, William D" sort="Hutchison, William D" uniqKey="Hutchison W" first="William D." last="Hutchison">William D. Hutchison</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurosurgery, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dostrovsky, Jonathan O" sort="Dostrovsky, Jonathan O" uniqKey="Dostrovsky J" first="Jonathan O." last="Dostrovsky">Jonathan O. Dostrovsky</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Physiology, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Moro, Elena" sort="Moro, Elena" uniqKey="Moro E" first="Elena" last="Moro">Elena Moro</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Deep brain stimulation</term>
<term>Levodopa</term>
<term>Long term</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Subthalamic nucleus</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Long terme</term>
<term>Noyau sousthalamique</term>
<term>Stimulation cérébrale profonde</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Subthalamic nucleus deep brain stimulation (STN-DBS) is effective in advanced Parkinson's disease (PD), but its effects on the levodopa response are unclear. We studied the levodopa response after long-term STN-DBS, STN-DBS efficacy and predictive value of preoperative levodopa response to long-term DBS benefit in 33 PD patients with bilateral STN-DBS. Patients were assessed using the Unified Parkinson's Disease Rating Scale preoperatively (with and without medications) and postoperatively (without medications or stimulation, with only medications or stimulation, and with both medications and stimulation). Levodopa response significantly decreased postoperatively by 31.1% at 3 years and 32.3% at 5 years, possibly related to the reduction in medication requirement, direct STN stimulation effect or PD progression. STN-DBS alone significantly improved motor scores (37.2% at 3 years and 35.1% at 5 years) and activities of daily living scores (27.1% at 3 years and 19.2% at 5 years). Anti-PD drugs were significantly reduced by 47.9% at 3 years and 39.8% at 5 years. However, the magnitude of the preoperative response to levodopa did not predict DBS benefit at 3 and 5 years.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PIBOOLNURAK (Panida)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LANG (Anthony E.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LOZANO (Andres M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MIYASAKI (Janis M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SAINT-CYR (Jean A.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>POON (Yu-Yan W.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HUTCHISON (William D.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>DOSTROVSKY (Jonathan O.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>MORO (Elena)</s1>
</fA11>
<fA14 i1="01"><s1>Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Bumrungrad International Hospital</s1>
<s2>Wattana, Bangkok</s2>
<s3>THA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurosurgery, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Physiology, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>990-997</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000149881420130</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>32 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0314955</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Subthalamic nucleus deep brain stimulation (STN-DBS) is effective in advanced Parkinson's disease (PD), but its effects on the levodopa response are unclear. We studied the levodopa response after long-term STN-DBS, STN-DBS efficacy and predictive value of preoperative levodopa response to long-term DBS benefit in 33 PD patients with bilateral STN-DBS. Patients were assessed using the Unified Parkinson's Disease Rating Scale preoperatively (with and without medications) and postoperatively (without medications or stimulation, with only medications or stimulation, and with both medications and stimulation). Levodopa response significantly decreased postoperatively by 31.1% at 3 years and 32.3% at 5 years, possibly related to the reduction in medication requirement, direct STN stimulation effect or PD progression. STN-DBS alone significantly improved motor scores (37.2% at 3 years and 35.1% at 5 years) and activities of daily living scores (27.1% at 3 years and 19.2% at 5 years). Anti-PD drugs were significantly reduced by 47.9% at 3 years and 39.8% at 5 years. However, the magnitude of the preoperative response to levodopa did not predict DBS benefit at 3 and 5 years.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Long terme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Long term</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Noyau sousthalamique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Subthalamic nucleus</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Núcleo subtalámico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Stimulation cérébrale profonde</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Deep brain stimulation</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>41</s5>
</fC07>
<fN21><s1>204</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 07-0314955 INIST</NO>
<ET>Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease</ET>
<AU>PIBOOLNURAK (Panida); LANG (Anthony E.); LOZANO (Andres M.); MIYASAKI (Janis M.); SAINT-CYR (Jean A.); POON (Yu-Yan W.); HUTCHISON (William D.); DOSTROVSKY (Jonathan O.); MORO (Elena)</AU>
<AF>Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital/Toronto, Ontario/Canada (1 aut., 2 aut., 4 aut., 6 aut., 9 aut.); Bumrungrad International Hospital/Wattana, Bangkok/Thaïlande (1 aut.); Department of Neurosurgery, University of Toronto, Toronto Western Hospital/Toronto, Ontario/Canada (3 aut., 5 aut., 7 aut.); Department of Physiology, University of Toronto/Toronto, Ontario/Canada (8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2007; Vol. 22; No. 7; Pp. 990-997; Bibl. 32 ref.</SO>
<LA>Anglais</LA>
<EA>Subthalamic nucleus deep brain stimulation (STN-DBS) is effective in advanced Parkinson's disease (PD), but its effects on the levodopa response are unclear. We studied the levodopa response after long-term STN-DBS, STN-DBS efficacy and predictive value of preoperative levodopa response to long-term DBS benefit in 33 PD patients with bilateral STN-DBS. Patients were assessed using the Unified Parkinson's Disease Rating Scale preoperatively (with and without medications) and postoperatively (without medications or stimulation, with only medications or stimulation, and with both medications and stimulation). Levodopa response significantly decreased postoperatively by 31.1% at 3 years and 32.3% at 5 years, possibly related to the reduction in medication requirement, direct STN stimulation effect or PD progression. STN-DBS alone significantly improved motor scores (37.2% at 3 years and 35.1% at 5 years) and activities of daily living scores (27.1% at 3 years and 19.2% at 5 years). Anti-PD drugs were significantly reduced by 47.9% at 3 years and 39.8% at 5 years. However, the magnitude of the preoperative response to levodopa did not predict DBS benefit at 3 and 5 years.</EA>
<CC>002B17; 002B17G; 002B02U01</CC>
<FD>Système nerveux pathologie; Parkinson maladie; Lévodopa; Long terme; Noyau sousthalamique; Stimulation cérébrale profonde</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux central</FG>
<ED>Nervous system diseases; Parkinson disease; Levodopa; Long term; Subthalamic nucleus; Deep brain stimulation</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Central nervous system</EG>
<SD>Sistema nervioso patología; Parkinson enfermedad; Levodopa; Largo plazo; Núcleo subtalámico</SD>
<LO>INIST-20953.354000149881420130</LO>
<ID>07-0314955</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000732 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000732 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:07-0314955
   |texte=   Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease

Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri